Teva Pharmaceutical to pay $519 million to resolve FCPA allegations

A Russian subsidiary of the Israel-based drug manufacturer agreed to plead guilty to participating in a $65 million bribe scheme in Russia, while the parent company will enter into a three-year deferred prosecution agreement.

Get unlimited access to all Global Investigations Review content